BetterLife Pharma Inc.
BETR
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 79.64% | -33.84% | -34.76% | -60.79% | -70.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -76.22% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.21% | -30.58% | -33.92% | -66.43% | -71.65% |
| Operating Income | -51.21% | 30.58% | 33.92% | 66.43% | 71.65% |
| Income Before Tax | -26.17% | 40.33% | 46.65% | 70.01% | 78.73% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.17% | 40.33% | 46.65% | 70.01% | 79.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -195.07% | -150.10% | -150.45% | -97.91% | 37.61% |
| Net Income | -82.50% | 23.81% | 31.47% | 68.93% | 82.73% |
| EBIT | -51.21% | 30.58% | 33.92% | 66.43% | 71.65% |
| EBITDA | 76.95% | 79.37% | 65.69% | 66.56% | 71.77% |
| EPS Basic | -61.11% | 41.11% | 47.57% | 75.90% | 85.51% |
| Normalized Basic EPS | -141.30% | 21.43% | 31.37% | 71.40% | 85.98% |
| EPS Diluted | -34.58% | 42.63% | 47.19% | 70.92% | 81.54% |
| Normalized Diluted EPS | -141.30% | 21.43% | 31.37% | 71.40% | 85.98% |
| Average Basic Shares Outstanding | 16.79% | 20.63% | 25.47% | 26.20% | 20.40% |
| Average Diluted Shares Outstanding | 20.99% | 20.63% | 25.47% | 26.20% | 20.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
